CHORD Therapeutics

CHORD Therapeutics is a clinical-stage pharmaceutical company based in Switzerland, dedicated to developing treatments for patients with rare, life-threatening, and severely disabling diseases. The company's lead drug candidate, CRD1, is being developed under orphan drug designation for the treatment of Neuromyelitis Optica (NMO) and Myasthenia Gravis (MG).

Chord Therapeutics differentiates itself by utilizing well-understood active substances with a history of clinical testing and uses in human patients. The company's lead medicinal product candidate, CRD1, leverages cladribine, a substance with a demonstrated safety and powerful, well-understood pharmacology, which is expected to provide benefits in various rare disorders. This approach substantially reduces development risks and enhances the likelihood of successful treatment innovation.

The company adopts a virtual biotech business model, outsourcing services to highly specialized vendors, enabling nimble operations while ensuring the acquisition of top-quality services in a cost-effective manner. Despite being run by a small team, Chord Therapeutics has gained the trust of Omega Funds, securing a $16.00M Series A investment on 13 October 2020.

With a clear dedication to introducing new treatments for patients affected by orphan diseases, Chord Therapeutics demonstrates a strong scientific rationale and a de-risked approach in its drug development, making it an intriguing prospect for potential investors and a promising player in the biotechnology and pharmaceutical industries.